Get notified when SUPN files again. Create a free account and we'll email you the moment its next filing is analyzed.

Get filing alerts
NASDAQ: SUPN SUPERNUS PHARMACEUTICALS, INC. 8-K

Supernus announces merger of equals with Indivior, creating $2.2B CNS leader

Filed August 3, 2026 · Period ending August 3, 2026 · ~1 min read

Key Changes

  • high

    Supernus merging with Indivior in all-stock transaction; shareholders receive 1.5401 Indivior shares per Supernus share, owning 43.5% of combined company. Indivior paying $1B dividend to pre-closing shareholders funded by $650M new debt.

    Exhibit 99.1 view on EDGAR →
  • high

    Combined company projects $2.2B revenue, $888M Adjusted EBITDA (41% margin) including $125M annual cost synergies. Pro forma net leverage under 1x at 0.99x.

    Exhibit 99.1 view on EDGAR →
  • high

    Transaction subject to shareholder and regulatory approvals, expected to close Q4 2026. Exchange ratio is fixed and will not adjust for share price changes. Competing proposals could emerge.

    Item 8.01 — Other Events verify on EDGAR →

2 more material changes behind this preview — plus the full narrative summary, section-by-section diffs against the prior filing, and verbatim quotes with EDGAR citations.

Read 3 full reports/month free No card required. Takes 30 seconds.

Want to see a complete report first? Today's free report (TRS 10-Q) is open in full — no account needed.

Partner

Trade SUPN commission-free

Open an account, get a free stock.

Sign up

Investing involves risk. Free stock terms apply.

Was this report useful?

Figures/quotes linked to EDGAR · Narrative written by AI · Aug 4, 2026 · How we verify